Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PLRX
PLRX logo

PLRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Pliant Therapeutics Inc (PLRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.160
1 Day change
-1.69%
52 Week Range
1.950
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Pliant Therapeutics Inc (PLRX) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are neutral to bearish, options data shows a lack of bullish sentiment, and there are no recent positive news catalysts or financial performance data to support a buy decision. The stock's price trend and lack of significant positive momentum do not align with the user's investment goals.

Technical Analysis

The MACD histogram is slightly positive at 0.00133 and expanding, indicating mild bullish momentum. However, RSI is neutral at 46.495, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upside potential in the short term.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
2

Positive Catalysts

  • Hedge funds are increasing their positions, with a 138.46% increase in buying over the last quarter.

Neutral/Negative Catalysts

  • No recent news, no significant insider trading activity, and no recent congress trading data. The stock has a 60% chance of declining slightly (-0.4%) in the next day and -0.38% in the next week.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes provided.

Wall Street analysts forecast PLRX stock price to rise
4 Analyst Rating
Wall Street analysts forecast PLRX stock price to rise
0 Buy
3 Hold
1 Sell
Hold
Current: 1.180
sliders
Low
2
Averages
3
High
4
Current: 1.180
sliders
Low
2
Averages
3
High
4
Canaccord
Hold
downgrade
$4 -> $3
AI Analysis
2026-03-13
Reason
Canaccord
Price Target
$4 -> $3
AI Analysis
2026-03-13
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Pliant Therapeutics to $3 from $4 and keeps a Hold rating on the shares. The firm said Pliant reported financial results and business highlights for 4Q25 and FY2025. As of December 31, 2025, the company had cash and cash equivalents of $192.4M. Management believes that the cash on hand is sufficient to fund planned operations into 2H28.
Piper Sandler
Overweight
to
NULL
downgrade
$4 -> $3
2026-03-12
Reason
Piper Sandler
Price Target
$4 -> $3
2026-03-12
downgrade
Overweight
to
NULL
Reason
Piper Sandler lowered the firm's price target on Pliant Therapeutics to $3 from $4 and keeps an Overweight rating on the shares. At Q4/FY25 earnings, Pliant provided a thoughtful update to their PLN-101095 program, the firm notes. Specifically, management detailed they have begun an accelerated development plan for PLN-101095 inclusive of beginning initiation activities for an open-label Phase 1b indication expansion trial which has first patient enrollment expected Q2 2026 and interim data 2027. Piper believes 2026 will be an informative year for Pliant as they continue to progress PLN-101095 development based on key Phase 1 data which will be presented at AACR 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PLRX
Unlock Now

People Also Watch